Lung cancer is a major health issue around the world. Among the different types, non-small cell lung cancer (NSCLC) is particularly tough to treat. However, a new drug named osimertinib is making waves. It's not your typical cancer treatment. Instead, it's designed to target specific EGFR gene mutat
Lung cancer is a tough opponent, especially when it's the non-small-cell kind (NSCLC). Doctors usually don't recommend a common treatment called EGFR-TKIs for a specific mutation called EGFR exon 20 insertion. Why? Because these mutations don't respond well to the treatment. But here's a twist: a sp
Nasopharyngeal carcinoma (NPC) is a big problem in Southeast Asia and southern China. Many people get it, but it's often found too late. Doctors have been using drugs that target a protein called EGFR to fight it. These drugs work at first, but the cancer cells find ways to resist them. Scientists
Lung cancer is a tough opponent, especially when it spreads to the brain. The blood-brain barrier, a protective shield, often stops treatments from reaching brain tumors. Osimertinib, a drug used to treat a specific type of lung cancer, can cross this barrier. However, some cancer cells develop resi
Lung cancer is a major health issue, with non-small cell lung cancer (NSCLC) making up most cases. This type of cancer often involves a gene called EGFR, which can be targeted with special drugs. However, these drugs often stop working over time. This is where things get interesting. Scientists have
Imagine a tiny protein named EGFR as a dancer in a ballet. It has partners, called ligands, that change its moves. Scientists recently explored seven of these partners and found something amazing. Each ligand makes EGFR move differently, like a dancer to different music. This might change how well E
Osimertinib has been a game-changer in treating advanced non-small-cell lung cancer (NSCLC). But how does it fare when used as a first-line treatment for patients who have had surgery and later experienced a recurrence? That's a question that needs answering. While we know that post-surgery recurren
